PMC

Flow of participants through the YES Study.

Baseline to 6 month % change in body fat, LBM, and BMD stratified by adherence (exercisers only)
Sample size for < 90 min/wk (n = 10), 90–150 min/wk (n = 15), and ≥ 150 min/wk (n = 12).

Baseline to 6 month % change in LBM stratified by stage, hormone therapy, age, and BMI
* p < .05 difference between exercisers and controls
Sample sizes for stage 0–I (exercisers, n = 24, usual care, n = 12), stage II–IIIA (exercisers, n = 12, usual care, n = 21), no HT (exercisers, n = 15, usual care, n = 10), tamoxifen (exercisers, n = 11, usual care, n = 8), AI (exercisers, n = 10, usual care, n = 15), < 56 yr (exercisers, n = 19, usual care, n = 16), ≥56 yr (exercisers, n = 17, usual care, n = 17, BMI < 30 (exercisers, n = 16, usual care, n = 20), and BMI ≥30 (exercisers, n = 20, usual care, n = 13).

Baseline to 6 month % change in BMC stratified by stage, hormone therapy, age, and BMI
* p < .05 difference between exercisers and controls
Sample sizes for stage 0–I (exercisers, n = 24, usual care, n = 12), stage II–IIIA (exercisers, n = 12, usual care, n = 21), no HT (exercisers, n = 15, usual care, n = 10), tamoxifen (exercisers, n = 11, usual care, n = 8), AI (exercisers, n = 10, usual care, n = 15), < 56 yr (exercisers, n = 19, usual care, n = 16), ≥56 yr (exercisers, n = 17, usual care, n = 17, BMI < 30 (exercisers, n = 16, usual care, n = 20), and BMI ≥30 (exercisers, n = 20, usual care, n = 13).

Baseline to 6 month % change in BMD stratified by stage, hormone therapy, age, and BMI
* p < .05 difference between exercisers and controls
Sample sizes for stage 0–I (exercisers, n = 24, usual care, n = 12), stage II–IIIA (exercisers, n = 12, usual care, n = 21), no HT (exercisers, n = 15, usual care, n = 10), tamoxifen (exercisers, n = 11, usual care, n = 8), AI (exercisers, n = 10, usual care, n = 15), < 56 yr (exercisers, n = 19, usual care, n = 16), ≥56 yr (exercisers, n = 17, usual care, n = 17, BMI < 30 (exercisers, n = 16, usual care, n = 20), and BMI ≥30 (exercisers, n = 20, usual care, n = 13).

Baseline to 6 month % change in body fat stratified by stage, hormone therapy, age, and BMI
* p < .05 difference between exercisers and controls
Sample sizes for stage 0–I (exercisers, n = 24, usual care, n = 12), stage II–IIIA (exercisers, n = 12, usual care, n = 21); no HT (exercisers, n = 15, usual care, n = 10), tamoxifen (exercisers, n = 11, usual care, n = 8), AI (exercisers, n = 10, usual care, n = 15); < 56 yr (exercisers, n = 19, usual care, n = 16), ≥56 yr (exercisers, n = 17, usual care, n = 17; BMI < 30 (exercisers, n = 16, usual care, n = 20), and BMI ≥30 (exercisers, n = 20, usual care, n = 13).